Semaglutide is anticipated to improve overall health, aid in weight loss, and help manage medical conditions associated with obesity and overweight
C2C exchanges have become a widely occurring phenomenon facilitated by city networks, funding programmes, and projects
Regarding bowel obstruction specifically , while there is no established direct causal relationship in the product literature, post-marketing surveillance for GLP-1-based therapies has identified rare reports of ileus (a form of bowel obstruction where the intestine stops moving properly) and intestinal obstruction
However, the FAERS (FDA Adverse Event Reporting System) received reports of alopecia or hair loss in people taking semaglutide and other GLP-1 medications like tirzepatide (Mounjaro, Zepbound)
Other Ingredients Maltodextrin
doi: 10.1038/s41419-022-05384-6 83 OuYWangSJLiDChuBGuW